Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Compound Guazijin Granules (复方瓜子金颗粒) is an approved traditional Chinese medicine (TCM) granule developed and manufactured by Jiangxi Tengwangge Pharmaceutical. It is formulated from a mixture of six herbal ingredients: Polygala japonica (Guazijin), Isatis tinctoria (Daqingye), Chrysanthemum indicum (Yejuhua), Lygodium japonicum (Haijinsha), Hedyotis diffusa (Baihuasheshecao), and Viola philippica (Zihuading). The formulation is indicated for the treatment of acute pharyngitis, acute exacerbation of chronic pharyngitis, and upper respiratory tract infections, presenting with symptoms such as sore throat, fever, and cough. It functions by clearing heat, detoxicating, relieving sore throat, dispersing swelling, and resolving phlegm.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Compound Guazijin Granules.